MX2019007942A - Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares. - Google Patents

Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares.

Info

Publication number
MX2019007942A
MX2019007942A MX2019007942A MX2019007942A MX2019007942A MX 2019007942 A MX2019007942 A MX 2019007942A MX 2019007942 A MX2019007942 A MX 2019007942A MX 2019007942 A MX2019007942 A MX 2019007942A MX 2019007942 A MX2019007942 A MX 2019007942A
Authority
MX
Mexico
Prior art keywords
cardiovascular diseases
treating cardiovascular
methods
pericarditis
acute
Prior art date
Application number
MX2019007942A
Other languages
English (en)
Inventor
Marchetti Carlo
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2019007942A publication Critical patent/MX2019007942A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se dirige a un método para el tratamiento de enfermedades cardiovasculares tales como infarto agudo de miocardio, aterosclerosis, insuficiencia cardíaca, accidente cerebrovascular, trombosis, carditis (lo que incluye miocarditis aguda, pericarditis aguda y pericarditis complicada), rechazo de aloinjerto cardíaco, cardiomiopatía, y enfermedades vasculares periféricas. El método comprende administrar a un sujeto que lo necesita dapansutrilo en una cantidad eficaz. Una vía de administración preferida es la administración oral.
MX2019007942A 2017-01-06 2018-01-05 Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares. MX2019007942A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443387P 2017-01-06 2017-01-06
US201762506843P 2017-05-16 2017-05-16
PCT/US2018/012625 WO2018129347A1 (en) 2017-01-06 2018-01-05 Methods for treating cardiovascular diseases

Publications (1)

Publication Number Publication Date
MX2019007942A true MX2019007942A (es) 2019-09-04

Family

ID=62791239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007942A MX2019007942A (es) 2017-01-06 2018-01-05 Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares.

Country Status (8)

Country Link
US (2) US11576888B2 (es)
EP (1) EP3565540B1 (es)
JP (1) JP7444432B2 (es)
CN (2) CN110167538B (es)
CA (1) CA3048494A1 (es)
ES (1) ES2970485T3 (es)
MX (1) MX2019007942A (es)
WO (1) WO2018129347A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3664786B1 (en) * 2017-08-11 2022-10-05 Olatec Therapeutics LLC Method for treating schnitzler's syndrome
CA3094307A1 (en) * 2018-03-21 2019-09-26 Olatec Therapeutics Llc Methods for treating melanoma
EP4045009A4 (en) * 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
WO2021194975A1 (en) * 2020-03-25 2021-09-30 Olatec Therapeutics Llc Method for treating diabetes
WO2021202305A1 (en) * 2020-03-31 2021-10-07 Olatec Therapeutics Llc Method for preventing or treating lung infection and lung inflammation
CN117897151A (zh) * 2021-08-19 2024-04-16 欧拉泰克治疗公司 用于治疗帕金森氏病的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651407B1 (en) * 2010-12-15 2016-12-21 Olatec Industries LLC 3-methanesulfonylpropionitrile for treating inflammation and pain
AU2013271836B2 (en) * 2012-06-05 2018-03-01 Olatec Therapeutics Llc Method for treating skin inflammatory diseases
US20130324603A1 (en) * 2012-06-05 2013-12-05 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain
CA2913154A1 (en) * 2013-05-21 2014-11-27 Virginia Commonwealth University Cryopyrin inhibitors for preventing and treating inflammation

Also Published As

Publication number Publication date
JP2020503358A (ja) 2020-01-30
CN116036069A (zh) 2023-05-02
CN110167538B (zh) 2022-11-29
EP3565540B1 (en) 2023-12-06
ES2970485T3 (es) 2024-05-29
EP3565540A1 (en) 2019-11-13
CA3048494A1 (en) 2018-07-12
JP7444432B2 (ja) 2024-03-06
US11576888B2 (en) 2023-02-14
US20190307718A1 (en) 2019-10-10
WO2018129347A1 (en) 2018-07-12
CN110167538A (zh) 2019-08-23
EP3565540A4 (en) 2020-09-23
US20230277496A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2019007942A (es) Uso de dapansutrilo para el tratamiento de enfermedades cardiovasculares.
PH12017501279A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
EA201891009A1 (ru) Соединения пиримидиндиона
MY194944A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
EA201892201A1 (ru) Неинвазивная диагностика неалкогольного стеатогепатита
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
EA202090715A1 (ru) Неинвазивная диагностика неалкогольных жировых дистрофий печени, неалкогольного стеатогепатита и/или фиброза печени
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
EA201791560A1 (ru) Порошковый состав для интраназального введения для лечения гипогликемии
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
PH12020500164A1 (en) Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
MX2021000154A (es) Metodos de tratamiento de fibrosis hepatica que usan inhibidores de calpaina.
CO2019013589A2 (es) Compuestos que contienen nitrógeno sustituido
EA201790699A1 (ru) Стабилизированные производные адреномедуллина и их применение
PH12017500795A1 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2019027299A3 (ko) 간세포성장인자를 발현하는 중간엽줄기세포를 유효성분으로 포함하는 혈관계 질환 예방 또는 치료용 약학 조성물
EA201991570A1 (ru) Амидные соединения и их применение
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
ZA202005083B (en) Solid forms of fasoracetam
EA201992386A1 (ru) Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение
MX2016017321A (es) Combinacicones y metodos para el tratamiento de dolor neuropatico.